BriaCell Therapeutics (NASDAQ:BCTX) Shares to Reverse Split on Wednesday, January 29th

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) are going to reverse split on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, January 28th.

BriaCell Therapeutics Price Performance

NASDAQ:BCTX opened at $0.40 on Monday. The firm has a market capitalization of $17.56 million, a PE ratio of -0.34 and a beta of 1.55. The business’s fifty day moving average price is $0.70 and its 200 day moving average price is $0.76. BriaCell Therapeutics has a 12 month low of $0.38 and a 12 month high of $4.61.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its earnings results on Monday, December 16th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). As a group, equities analysts anticipate that BriaCell Therapeutics will post -1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a report on Thursday, December 12th.

Hedge Funds Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.